natgillin/translations-raw huggingface dataset:
It has been found that the beneficial and unexpected effects of the pharmaceutical methods of the invention can be obtained by administering the CD19xCD3 bispecific single chain antibody in a daily dose of 10 microgram to 100 microgram per square meter body surface area. 
Konstrukt za uporabu prema patentnim zahtjevima 1 do 9, naznačen time što se CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca daje u dnevnoj dozi od 15 ug, 30 ug, 60 ug ili 90 ug po kvadratnom metru površine tijela pacijenta.
R is a moiety comprising at least one functional group selected from the group consisting of halo, cyano, hydroxyl, sulfonyl, aldehyde, carbonyl, carboxyl, ether, ester, carboxamide, amine, hydrazinyl, ammonium, azide and 5- or 6-membered heterocyclic group; 
R je vrsta koja obuhvaća barem jednu funkcionalnu skupinu izabranu iz grupe koja obuhvaća halo, cijano, hidroksil, sulfonil, aldehid, karbonil, karboksil, eter, ester, karboksamid, amin, hidrazinil, amonij, azid i 5- ili 6-eročlanu heterocikličku skupinu;
The process according to claim 1, wherein the compound of Formula IIa is a compound of Formula II and the sulphonating agent is tosyl chloride. 
Postupak prema zahtjevu 1, naznačen time da spoj formule Ila je spoj formule II i sredstvo za sulfoniranje je tosil klorid t>&
The solids were washed thoroughly with tetrahydrofuran and the combined filtrates were concentrated under vacuum to 600 ml. 
Krute supstancije se potpuno isperu s tetrahidrofuranom i spojeni filtrati se koncentriraju pod vakuumom na 600 ml.
Conversely, the collar (2) used in the third embodiment of the invention is very cost effective, being a plastic moulded part, since the wall will be scraped using the front edges (20a) of the counter-collar (20) as reference, with the counter-collar having a very low cost because of box-shaped sheet construction. 
Suprotno tome, okvir (2) koji se koristi u trećem ostvarenju ovog izuma je vrlo nepovoljan po cijeni, budući daje to komad koji je izliven iz plastike, pa će za vrijeme uređivanja zida biti korišteni prednji rubovi (20a) protu okvira (20) kao referenca, koji protu-okvir ima vrlo nisku cijenu budući daje načinjen od lima kojemu se daje oblik kutije.
the IL-22 fusion protein or pharmaceutical composition is administered until there is complete wound closure; or the subject is coadministered with at least one additional therapeutic agent for accelerating or improving wound healing; or 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 38 do 43, naznačen time, da se on pojedincu daje zajedno s najmanje jednim dodatnim terapeutskim sredstvom za ubrzanje ili poboljšanje zacijeljivanja rana.
the effector moiety is linked through an oxime or hydrazone linkage to a saccharide residue of the glycan; and 
efektorski dio je povezan preko vezanja oksima ili hidrazona na saharidni ostatak glikana; i
X is iodide; X' is fluoride, bromide or chloride; and z is greater than 0 and less than 1, and preferably z is from 0.05 to 0.95. 
X je drugi halidni anion različit od prvog halidnog aniona i zje veći od 0 a manji od 1, a poželjno je da je z od 0, 05 do 0, 95.
iii) filtering off the solid and drying the same for 4 hours under vacuum at room temperature. 
(1li) filtriranje od krutina i sušenje u vremenu od 4 sata pod vakuumom na sobnoj temperaturi.
H-Asp(O—P2)-Trp-Pro-OH through attachment of the Gly of the 2-3 eptifibatide sequence to the Asp of the 4-6 eptifibatide sequence, thereby forming the 2-6 eptifibatide sequence. 
H-Asp(O-P>)-Trp-Pro-OH preko vezivanja Gly ostatka fragmenta 2-3 eptifibatida na Asp ostatak fragmenta 4-6 eptifibatida, da na taj način nastane fragment 2-6 eptifibatida.
with an oxalic diester of formula V wherein R14 is -(C1-C6)-alkyl, to give a compound of formula VI. 
O R14-0O O gdje je R14 -(C,-Ce)-alkil, kako bi se dobilo spoj formule VI.
A method for reducing growth lag time of a viral culture comprising, administering to a host cell culture infected with a virus, a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers wherein the composition reduces lag time of the viral cultures in the host cell culture compared to a control viral culture without administering one or more ethylene oxide propylene oxide (EO-PO) block copolymers, wherein the EO-PO block copolymers comprise poloxamer 407, poloxamer 403 or a combination thereof wherein the concentration of EO-PO block copolymer is from 0.063% to 3.0%. 
Metoda za reduciranje faze prilagodbe kulture virusa sadrži, primjenjujući na stanicu kulture domaćina inficiranu virusom, spoj koji sadrži jedan ili više etilen-oksid-propilen-oksid (EO-PO) blok kopolimera, gdje EO-PO blok kopolimera sadrži poloksamer 407 (pluronski F127), poloksamer 403 (pluronski P123) ili njihovu kombinaciju, gdje je koncentracija EO-PO bloka kopolimera od otprilike 0,001 % do otprilike 3,0 % (m/V) i gdje spoj reducira fazu prilagodbe kultura virusa u usporedbi s kontroliranom kulturom virusa bez primjene jednog ili više EO-PO kopolimera.
A compound for use according to claim 5, wherein the disease state is selected from a group consisting of: chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, antiogenesis, invasion metastasis, melanoma, Karposi's sarcoma, acute and chronic bacterial and virual infections, sepsis, transplantation rejection, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airways inflammation. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: kronična opstruktivna plućna bolest, anafilaktički šok, fibroza, psorijaza, alergijske bolesti, astma, inzult, ishemija-reperfuzija, agregacija/aktivacija trombocita, atrofija/hipertrofija skeletnih mišića, novačenje leukocita u tkivu raka, antiogeneza, invazivna metastaza, melanom, Kaposijev sarkom, akutne i kronične bakterijske i virusne infekcije, sepsa, odbacivanje transplantacije, odbacivanje presatka, glomeruloskleroza, glomerulonefritis, progresivna fibroza bubrega, ozljede endotela 1 epitela u plućima, te upala dišnih putova pluća.
Ra and Rb are independently selected from the group consisting of hydrogen, C1-6alkyl, and C1-6alkoxycarbonyl; alternatively, when Ra and Rb are each other than hydrogen, Ra and Rb are optionally taken together with the nitrogen atom to which they are both attached to form a five to eight membered monocyclic ring; 
ili kada Ra i Rb nisu vodik, Ra i Rb su proizvoljno uzeti zajedno sa dušikom za koji su oba vezani da formiraju peto- do osmo-člani monociklični prsten; i L je izabran iz grupe koju čine O, S i N (Rd); gdje Rd predstavlja vodik, C1-6 alkil, ili aril.
The composition for use of any one of the preceding claims, wherein the inhibitor of the coagulation fXa is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, DU-176b, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof. 
Pripravak za uporabu prema zahtjevu 10 ili 11, naznačen time da je inhibitor faktora Xa odabran iz skupine koju čine fondaparinuks, idraparinuks, biotinilirani idraparinuks, enoksaparin, fragmin, NAP-5, rNAPc2, inhibitor faktora tkivnog puta, DX-9065a, YM-60828, YM-150, apiksaban, rivaroksaban, PD-348292, otamiksaban, DU-176b, LY517717, GSK913893, razaksaban, heparin niske molekularne težine, betriksaban ili njihova farmaceutski prihvatljiva sol, te njihove kombinacije.
a stream that, when entering into the pyrolysis chamber, is substantially formed by said CO2 as supplied and that, by flowing within the pyrolysis chamber, becomes richer in pyrolysis products forming said gas mixture containing pyrolysis products, on the one hand, and 
struje koju prilikom ulaska u komoru za pirolizu (52) uglavnom stvara dovod CO2, i koja protokom kroz komoru za pirolizu (52) postaje bogatija produktima pirolize, koji formiraju smjesu plinova (30), koja sadrže navedene produkte, s jedne strane, i
The modified soluble FGF receptor Fc fusion of claim 3, wherein all N-glycosylation sites of the FGF receptor moiety are occupied with a N-glycan. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 6, naznačena time što su zauzeta sva N-glikozilacijska mjesta u FGF receptorskom ostatku.
A method for entropy decoding a current picture of a video comprising: obtaining, from a Picture Parameter Set (PPS) of the current picture in a bitstream, first information indicating whether a dependent slice segment may be used in the current picture; 
jedinicu za dobivanje konfiguriranu za dobivanje, iz skupa parametara slike (PPS) trenutne slike u toku bitova, prve informacije koja pokazuje da li se ovisni segment odsječka može koristiti u trenutnoj slici;
The material according to any of claims 1 to 11, comprising at least one synergist for the chlorinated flame retardants and/or chlorinated plasticizers and/or chlorinated polymers, preferably antimony trioxide or zinc borate or a mixture thereof. 
Materijal prema bilo kojem od patentnih zahtjeva od 1 do 10 naznačen time da sadrži bar jedno sinergističko sredstvo za klorirane retardante (usporivače plamena) i/ili klorirane plastifikatore i/ili klorirane polimere, poželjno antimon trioksid ili cinkov borat ili njihovu smjesu.
It is, for example, possible to add at least one composition b) to at least one component a), or vice versa, optionally with stirring and/or optionally with heating. 
- barem jednu komponentu bl), barem jednu komponentu b2), barem jednu komponentu b3), barem jednu komponentu b4) i barem jednu komponentu b5).
A Roseburia hominis flagellin, and/or a polynucleotide sequence encoding said Roseburia hominis flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in restoring the immunological tolerance of a subject. 
Roseburia hominis flagelin, i/ili polinukleotidna sekvenca, i/ili vektor, i/ili stanica domaćin, uključujući bakteriju, koja sadrži navedeni vektor, i/ili stanica domaćin, uključujući bakteriju, koja sadrži navedenu polinukleotidnu sekvencu, za upotrebu prema bilo kojem od zahtjeva 16, naznačena time da je navedeni Roseburia hominis flagelin polipeptid koji je najmanje 99% identičan sa SEQ ID NO 2 ili SEQ ID NO 4, pri čemu je polinukleotidna sekvenca koja kodira navedeni Roseburia hominis flagelin najmanje 99% identična sa SEQ ID NO 2 ili SEQ ID NO 4 ili polinukleotidna sekvenca koja je najmanje 99% identična sa SEQ ID NO 1 ili SEQ ID NO 3.
The method according to claim 21, wherein the antibody comprises a heavy chain wherein the variable domain comprises a CDR having the sequence given in SEQ ID NO: 1 for CDRH1, SEQ ID NO: 2 for CDRH2, and SEQ ID NO: 3 for CDRH3 and a light chain and wherein the variable domain comprises a CDR having the sequence given in SEQ ID NO: 4 for CDRL1, SEQ ID NO: 5 for CDRL2 and SEQ ID NO: 6 for CDRL3. 
Postupak prema patentnom zahtjevu 21, pri čemu antitijelo sadrži teški lanac gdje varijabilna domena sadrži CDR koji ima sekvencu danu u SEQ ID NO:1 za CDRHI, SEQ ID NO:2, za CDRH2 i SEQ ID NO:3 za CDRH3 i laki lanac pri čemu varijabilna domena sadrži CDR koji ima sekvencu danu u SEQ ID NO:4 za CDRLI, SEQ ID NO:5 za CDRL2 i SEQ ID NO:6 za CDRL3.
is phosphate or phosphate salt and is hydrogen, and (b) 
je fosfat ili fosfatna sol i A2 je vodik, te
wherein the respirable suspending particles are perforated microstructures comprising DSPC (1,2-disteroyl-sn-glycero-3-phosphocholine) and calcium chloride. 
gdje najmanje jedna vrsta suspendirajućih čestice sadrže perforirane mikrostrukture, gdje perforirane mikrostrukture sadrže DSPC (1,2-disteroil-sn-glicero-3-fosfokolin) i kalcijev klorid.
Method of generating reconstructed block 
POSTUPAK GENERIRANJA REKONSTRUIRANOG BLOKA
A compound as defined in any one of the preceding claims for use as a medicament. 
Tvar kako je definirana u patentnom zahtjevu 1 za uporabu kao lijek.
R9′ is independently selected from H, F, Cl, CN, CHF2, and CF3; and n, at each occurrence, is an integer selected from 1 and 2. 
R* je nezavisno odabrano od H, F, Cl, CN, CHF., i CFg; 1 n, u svakom slučaju, je cijeli broj izabran od 1 12.
The vehicle of claim 5, wherein a flow direction of the heat conduction medium in the first group of channels is opposite to a flow direction of the heat conduction medium in the second group of channels. 
Sustav za toplinsku disipaciju koji je pogodan za uporabu unutar vozila, te sustav za toplinsku disipaciju sadrži: izmjenjivač topline; prvi pasivni hladnjak i drugi pasivni hladnjak koji su smješteni sprijeda i bočno pomaknuti na suprotne strane izmjenjivača topline;
Method according to claim 1, wherein the boronic acid derivative, borolane, borinane or diboronic acid reagent is selected from: wherein R', R", Ra, Rb, Rc, Rd, Re and Rf represent independently of each other a substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms. 
ov o pri čemu R, R", R%, R", R" R"i RI! predstavljaju nezavisno jedan od drugog supstituiranu ili nesupstituiranu, linearnu ili razgranatu alkilnu grupu s 1 do 10 ugljikovih atoma ili cikloalkilnu grupu s 3 do 10 ugljikovih atoma.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. 
Stručnjak će uvidjeti da određeni supstituenti u spojevima iz ovog izuma mogu biti uvedeni standardnim reakcijama aromatske supstitucije ili generirani konvencionalnim modifikacijama funkcionalnih skupina bilo prije ili odmah nakon gore navedenih postupaka, i kao takvi su uključeni u aspekt postupaka iz ovoga izuma.
Examples of diseases/disorders wherein increased clot formation is desirable include, but is not limited to, hemorrhages, including brain hemorrhages, as well as patient with severe uncontrolled bleedings, such as trauma. Further examples include patients undergoing living transplantations, patients undergoing resection and patients with variceal bleeding. Another widespread disease/disorder in which it is contemplated that the polypeptides of the invention will be useful for increased clot formation is hemophilia, e.g. von Willebrand disease, hemophilia A, hemophilia B or hemophilia C. 
Uporaba u skladu sa zahtjevom 42, naznačena time, da je navedo oboljenje ili poremećaj izabran iz skupine koju čine hemoragije, uključujući hemoragije mozga, snažna nekontrolirana krvarenja poput trauma, krvarenja kod pacijenata prilikom transplatacija ili resekcija, krvarenja kod varičela i hemofilija. Varijanta kakva je određena u bilo kojem od zahtjeva 1-36, naznačena time, da je za uporabu u liječenju oboljenja ili poremećaja kod kojih je poželjno formiranje ugruška. .
combining said population of lipoprotein complexes with one or more pharmaceutically acceptable excipients. 
(b) miješanje lipoproteinskih kompleksa s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
An immunogenic or vaccine composition comprising an isolated polypeptide having at least 85% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4 and a pharmaceutically acceptable carrier or excipient. 
Imunogenični sastav 1li cjepivo sadrži izolirani polipeptid koji ima najmanje 85% identičan slijed aminokiselinskom slijedu kako je navedeno u SEQ ID NO:4 i farmaceutski prihvatljivi nosač ili ekscipijens.
Measurement of the Refractive Index of a Given Formulation 
Broj objave europskog patenta:
3 depicts the method of synthesis for 42-O-(D-Fructosylcarbonyl)rapamycin. 
Slika 3 prikazuje postupak sinteze 42-O-(D-fruktozilkarbonil)rapamicina.
In the compounds of the formulae V, XVIII, XIX and XX the groups Het, X, Y, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. 
Bi ib R' M gdje su Het, X, Y, R!, R? i R* definirani kao u patentnim zahtjevima 1 do 9, gdje, uz to, sve funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, a L' se može nukleofilno supstituirati izlaznom skupinom.
adding the antibody defined in any one of claims 1-14 to a sample taken from a subject; and 
- < dodavanje protutijela definiranog prema bilo kojem od zahtjeva 1-14 uzorku uzetom od subjekta; i
The odour-absorbing composition according to claim 2, wherein the weight ratio of the amount of said a-cyclodextrins to the amount of said B-, and Y-cyclodextrins ranges from 4:1 to 1:1, more preferably from 2:1 to 1:1. 
Sastav koji apsorbira neugodne mirise prema patentnom zahtjevu 2, naznačen time, da se maseni omjer količine navedenih a-ciklodekstrina prema količini navedenih B- i Y-ciklodekstrina, nalazi u rasponu od 4:1 do 1:1, još poželjnije od 2:1 do 1:1.
A fusion protein comprising the signal polypeptide of claim 1 operably linked to a heterologous polypeptide. 
Fuzijski protein koji sadrži polipeptidnu signalnu sekvencu prema zahtjevu 1 naznačen time da je operabilno vezan na heterologni polipeptid.
is a single bond, or an ethylene group optionally substituted by a lower alkyl group; R1a and R1b are independently a hydrogen atom, a lower alkyl group or a hydroxy-lower alkyl group, or together form a lower alkylene group wherein one or two or more methylene groups constituting the lower alkylene group may be independently replaced by an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a vinylene group or a group of -N(R1c)-, and/or substituted by a hydroxyl group or a lower alkyl group; 
je jednostruka veza, ili etilen skupina po izboru supstituirana nižom alkilnom skupinom; a i R1b su nezavisno atom vodika, niža alkilna skupina ili hidroksi-niža alkilna skupina, ili zajedno formiraju nižu alkilen skupinu gdje jedna ili više metilenskih skupina koje čine nižu alkilen skupinu mogu nezavisno biti zamijenjene atomom kisika, atomom sumpora, sulfinil skupinom, sulfonilom skupinom, karbonil skupinom, vinilen skupinom ili skupinom -N(R1c)-, i/ili supstituirane hidroksil skupinom ili nižom alkilnom skupinom;
94% (no change) brittleness 67% (1 grade 
94% (bez promjene) 67% (poboljšanje 1. stupnja)
D is an optionally substituted azetidinyl, optionally substituted bicyclo[2.2.2]octanylene, optionally substituted bicyclo[2.2.1]heptylene, optionally substituted bicyclo[2.1.1]hexylene, optionally substituted cyclobutylene, optionally substituted cyclopentylene, optionally substituted cyclohexylene, optionally substituted bicyclo[2.2.1]hept-2-enylene, optionally substituted piperidinyl, or optionally substituted pyrrolidinyl; 
D je po izboru supstituirani azetidinil, po izboru supstituirani biciklo[2.2.2]oktanilen, po izboru supstituirani biciklo[2.2.1]heptilen, po izboru supstituirani biciklo[2.1.1]heksilen, po izboru supstituirani ciklobutilen, po izboru supstituirani ciklopentilen, po izboru supstituirani cikloheksilen, po izboru supstituirani biciklo[2.2.1]hept-2-enilen, po izboru supstituirani piperidinil ili po izboru supstituirani pirolidinil;
The isolated cell according to claim 10, wherein said cell is bacterial or a mammalian cell. 
Izolirana stanica prema zahtjevu 9, naznačena time da navedena stanica je bakterijska stanica ili stanica sisavca.
The combination for use according to claim 7, wherein treatment with a dose of at least 1.5 g/day metformin and of at least 10 units/day of insulin alone for three months does not adequately control diabetes mellitus type 2 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 7, naznačena time što liječenje samo dozom od najmanje 1,5 g dnevno metformina i najmanje 10 jedinica dnevno inzulina tijekom tri mjeseca nije dovoljna kontrola za dijabetes melitus tip 2.
Compounds of Formula XI are known or can be prepared using known processes for the preparation of analogous compounds. 
Spojevi prikazani Formulom IX su poznati, ili ih se može pripraviti koristeći poznate postupke za pripravu analognih spojeva.
A compound, stereoisomer, tautomer, oxide, or ester of Formula (V) or a pharmaceutically acceptable salt thereof: 
NŽ2f Ki Å ili njegov solvat, oksid, ili njegova farmaceutski prihvatljiva sol.
The controlled release pharmaceutical composition according to any one of the claims 1-4, wherein the release of the fumaric acid ester is as follows: within the first 7 hours after start of the test at the most about 98% w/w of the total amount of the fumaric acid ester contained in the composition is released. 
unutar prva 3 sata nakon početka ispitivanja oslobodi se najviše 70% w/w ukupne količine dimetilfumarata sadržanog u sastavu, i unutar prva 4 sata nakon početka ispitivanja oslobodi se najviše 92% w/w ukupne količine dimetilfumarata.
Neramexane or a pharmaceutically acceptable salt thereof, for use in the treatment of hearing loss in patients suffering from tinnitus. 
Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu kod liječenja ili prevencije tinitusa, naznačen time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus).
The gel according to claim 1, characterized by comprising a base in an amount of 0.1 to 0.8% by weight. 
Gel temeljem bilo kojeg od prethodnih zahtjeva, naznačen time da sadrži bazu u količini od 0,1 do 0,8 % masenog udjela.
n independently represents 0, 1, 2, 3 or 4; 
n neovisno predstavlja cijeli broj jednak 2, 3 ili 4;
An isolated antibody or antigen binding fragment thereof comprising a VH region and a VL region wherein said VH and VL regions comprise, respectively, polypeptides selected from the group consisting of: 
Izolirano antitijelo ili antigen vezujući fragment istog koji se može specifično vezati na Sp35 i koji može antagonizirati Sp35, pri čemu je antitijelo ili fragment istog odabrano iz skupine koja se sastoji od:
is a 3- to 10-membered ring or a 7- to 11-membered ring system, each ring or ring system containing ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N, wherein up to 3 carbon atom ring members are independently selected from C(=O) and C(=S) and the sulfur atom ring members are independently selected from S(=O)n(=NR24)z, each ring or ring system optionally substituted with up to 5 substituents independently selected from R14; 
R je3- do 10-člani prsten ili 7- do 11-člani sustav prstena, pri čemu svaki prsten ili sustav prstena sadrži članove prstena koji su izabrani od atoma ugljika i do 4 heteroatoma nezavisno izabrana od maksimalno 2 O, maksimalno 2 S i maksimalno 4 N, gdje su maksimalno 3 atoma ugljika koji su članovi prstena nezavisno izabrani od C(=0) 1 C(=S) i članovi prstena atomi sumpora su nezavisno izabrani od S(=0),(SNR*),, pri čemu je svaki prsten ili sustav prstena izborno supstituiran sa do 5 supstituenata nezavisno izabrana od R'%
A compound or an enantiomer, diastereomer, or salt thereof, for use according to claim 1, wherein the compound is: 
Spoj prema patentnom zahtjevu 1, gdje je spoj [image] ili sol tog spoja.
(R)-(−)-3-(carbamoylmethyl)-5-methylhexanoic acid may optionally be purified according to conventional techniques, for example, crystallisation in a suitable solvent. 
Postupak prema patentnom zahtjevu 7, naznačen time, da se (R)-(-)-3- (karbamoilmetil)-5-metilheksanska kiselina izolira filtriranjem nakon zakiseljavanja.
The combined organic layers were washed with water (5 mL×2) followed by saturated aqueous NaCl (5 mL×2). 
Spojeni organski slojevi isprani su sa vodom (5 mL x 2) nakon čega je uslijedila zasićena vodena otopina NaCI (5 mL x 2).